Protara Therapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Rhea-AI Summary

Protara Therapeutics (Nasdaq: TARA) granted inducement equity awards to a newly hired employee under Nasdaq Listing Rule 5635(c)(4). The Compensation Committee approved 10,200 stock options (exercise price $7.04) granted on Feb 2, 2026 and 5,100 RSUs with a grant date of Apr 1, 2026.

Options vest over four years (25% at one year, then monthly over 36 months). RSUs vest over three years in three equal annual installments, subject to continued service.

Key Figures

Inducement stock options: 10,200 options Inducement RSUs: 5,100 RSUs Option exercise price: $7.04 per share +5 more

8 metrics

Inducement stock options 10,200 options Granted to one new employee under Inducement Plan

Inducement RSUs 5,100 RSUs Granted to one new employee under Inducement Plan

Option exercise price $7.04 per share Closing trading price on February 2, 2026 grant date

Option vesting cliff 25% Vests on one-year anniversary of option grant date

Post-cliff option vesting 1/36 monthly Remaining option shares vest monthly over 36 months

RSU vesting term 3 years RSUs vest in three equal annual installments

RSU grant date April 1, 2026 Grant date for inducement RSU awards

Stock price vs 52-week high -9.46% Current price relative to $7.82 52-week high

Market Reality Check

Price: $7.04 Vol: Volume 1,046,775 is below...

normal vol

$7.04 Last Close

Volume Volume 1,046,775 is below the 20-day average of 1,232,377 ahead of this routine HR news. normal

Technical Shares at $7.08 are above the 200-day MA of $4.27 and trading 9.46% below the $7.82 52-week high.

Peers on Argus

TARA gained 1.14% while peers showed mixed moves (e.g., EQ up 5.19%, IOBT down 9...

TARA gained 1.14% while peers showed mixed moves (e.g., EQ up 5.19%, IOBT down 9.06%). With no peers in the momentum scanner and varied directions, today’s action appears stock-specific rather than a sector-wide move.

Common Catalyst Another peer, Equillium (EQ), also reported inducement grants under Nasdaq Listing Rule 5635(c)(4), suggesting a governance/compensation theme rather than a clinical or regulatory catalyst.

Historical Context

5 past events · Latest: Jan 22 (Positive)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Jan 22	Clinical data update	Positive	+2.4%	Planned presentation of updated Phase 2 ADVANCED-2 data in NMIBC at ASCO GU.
Jan 12	Corporate/milestones	Neutral	-8.9%	Highlighted 2026 milestones and an ~$86M offering extending cash runway into 2028.
Jan 07	Conference appearance	Neutral	+11.1%	Announcement of participation in the 44th J.P. Morgan Healthcare Conference.
Jan 07	Phase 3 trial start	Positive	+11.1%	First patient dosed in Phase 3 THRIVE-3 IV Choline Chloride trial for PS patients.
Jan 05	FDA designations	Positive	+0.2%	FDA Breakthrough Therapy and Fast Track designations for TARA-002 in pediatric LMs.

Pattern Detected

Recent news has largely been positive (regulatory designations, trial progress, milestones), with price reactions sometimes diverging from the constructive fundamental tone.

Recent Company History

Over the past month, Protara issued several notable updates. On Jan 5, the FDA granted Breakthrough Therapy and Fast Track designations for TARA-002. On Jan 7, the company announced first dosing in the Phase 3 THRIVE-3 trial and a J.P. Morgan conference appearance, which coincided with double-digit gains. A mid-January update highlighted an $86 million offering and 2026 milestones, followed by news of interim ADVANCED-2 Phase 2 data to be presented at ASCO GU. Today’s inducement grants fit into this pattern of ongoing corporate and development activity.

Market Pulse Summary

This announcement details equity inducement grants—10,200 stock options at $7.04 and 5,100 RSUs—with...

Analysis

This announcement details equity inducement grants—10,200 stock options at $7.04 and 5,100 RSUs—with multi-year vesting tied to continued service. It follows a stretch of impactful updates, including FDA designations for TARA-002 and initiation of the Phase 3 THRIVE-3 trial. Investors may monitor upcoming interim data presentations and regulatory interactions, as well as how ongoing equity compensation shapes ownership and incentives over time.

Key Terms

nasdaq listing rule 5635(c)(4), non-qualified stock options, restricted stock units (rsus), exercise price

4 terms

nasdaq listing rule 5635(c)(4) regulatory

"as inducements material to the new employee’s employment in accordance with Nasdaq Listing Rule 5635(c)(4)"

NASDAQ Listing Rule 5635(c)(4) is a rule that requires a company to get approval from its shareholders before selling a large amount of its shares, usually over 20%. This helps protect investors by making sure the company doesn't flood the market with new shares without their say, which could lower the stock's value.

non-qualified stock options financial

"announced the recent grants of inducement non-qualified stock options and restricted stock units"

Non-qualified stock options are a type of employee benefit that gives individuals the right to buy company shares at a set price, usually lower than the market value, within a certain period. Unlike other options that may have special tax advantages, these options are taxed as income when exercised, which can affect how much money the employee or investor ultimately gains. They are important because they can influence company compensation strategies and impact the financial outcomes for employees and investors.

restricted stock units (rsus) financial

"inducement non-qualified stock options and restricted stock units (RSUs) to one newly-hired employee"

Restricted stock units (RSUs) are a type of company promise to give employees shares of stock in the future, usually after certain conditions like working for a set time. They are like a gift promised today that you receive later, which can become valuable if the company's stock price goes up. RSUs matter because they are a way companies reward employees and can be a significant part of compensation.

exercise price financial

"Such option awards were granted on February 2, 2026 and have an exercise price of $7.04 per share"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

AI-generated analysis. Not financial advice.

NEW YORK, Feb. 02, 2026 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA) (“Protara” or the “Company”), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced the recent grants of inducement non-qualified stock options and restricted stock units (RSUs) to one newly-hired employee.

The Compensation Committee of Protara’s Board of Directors approved an aggregate of 10,200 stock option awards and 5,100 RSU awards to one new employee from the Inducement Plan, as inducements material to the new employee’s employment in accordance with Nasdaq Listing Rule 5635(c)(4). Such option awards were granted on February 2, 2026 and have an exercise price of $7.04 per share, Protara’s closing trading price on the grant date. Such RSU awards will have a grant date of April 1, 2026.

All option awards vest over four years, with 25% of the underlying shares vesting on the one-year anniversary of the grant date and 1/36th of the underlying shares vesting monthly thereafter over 36 months. All RSU awards vest over three years, with 33 1/3% of the shares underlying the RSU award vesting on each of the three consecutive anniversaries of the grant date. The vesting of all option and RSU awards is subject to the employee's continued service with the company through the applicable vesting dates.

About Protara Therapeutics, Inc.

Protara is a clinical-stage biotechnology company committed to advancing transformative therapies for people with cancer and rare diseases. Protara’s portfolio includes its lead candidate, TARA-002, an investigational cell-based therapy in development for the treatment of non-muscle invasive bladder cancer (NMIBC) and lymphatic malformations (LMs). The Company is evaluating TARA-002 in an ongoing Phase 2 trial in NMIBC patients with carcinoma in situ (CIS) who are unresponsive or naïve to treatment with Bacillus Calmette-Guérin (BCG), as well as a Phase 2 trial in pediatric patients with LMs. Additionally, Protara is developing IV Choline Chloride, an investigational phospholipid substrate replacement for patients on parenteral nutrition who are otherwise unable to meet their choline needs via oral or enteral routes. For more information, visit www.protaratx.com.

Company Contact:

Justine O'Malley Protara Therapeutics
Justine.OMalley@protaratx.com
646-817-2836

Source: Protara Therapeutics

FAQ

What equity inducements did Protara (TARA) approve on February 2, 2026?

Protara approved 10,200 non‑qualified stock options and 5,100 RSUs as inducements for one newly hired employee. According to the company, options were granted Feb 2, 2026 and RSUs carry an April 1, 2026 grant date.

What is the exercise price and grant date for the options granted by Protara (TARA)?

The exercise price is $7.04 per share, equal to Protara's closing price on the grant date. According to the company, the option awards were granted on February 2, 2026.

How do the Protara (TARA) option awards vest for the new employee?

Options vest over four years: 25% vests at the one‑year anniversary, then 1/36th monthly for 36 months. According to the company, vesting is conditioned on continued service through each vesting date.

What is the vesting schedule for the RSUs granted by Protara (TARA)?

RSUs vest over three years with 33 1/3% vesting on each annual anniversary of the grant date. According to the company, the RSU grant date is April 1, 2026 and vesting requires continued employment.

Are Protara's (TARA) inducement awards tied to Nasdaq rules and why does that matter?

Yes, the awards were made under Nasdaq Listing Rule 5635(c)(4) as inducements to employment. According to the company, this permits grant of compensation outside shareholder-approved plans when required for hiring.